Insulin like growth factor 1 or IGF-1 is commonly labeled under the name somatomedin C. This protein is encoded as IGF1 in humans, and can be synthesized under the name sulfation factor, for use in animal research studies. This is a hormone that has a very similar molecular structure to that of insulin and is critical to development and growth in young animals. Adults still see use from IGF LR3, due to its anabolic effects. The synthetic analog of IGF-1 is often studied for its potential management of growth failure.
The IGF molecule contains 70 amino acids which are arranged in a single chain that also includes three intramolecular disulfide bridges. This chemical has been determined to have nonsuppressible insulin like activity, which is used by the body to bind with receptors on a variety of cell tissues. This will create signaling pathway that will stimulate proliferation and cell growth while inhibiting cell death.
Regulation of Apoptosis
Transforming growth factor can be induced to a castrated prostate with the speculation that this will assist in mediating apoptosis of epithelial cells from prostatic involution.
The evidence of this effect is where to buy igf-1 lr3 seen on applying the chemical to prostatic epithelial cells in vitro with an NRP-152 nontumorigenic as well as NRP 154 tumorigenic rat prostatic epithelial cells.
Transforming growth factor helps to induce apoptosis in the cell lines within 24 hours. This was evidenced by the decrease in cell viability as well as internucleosomal DNA fragmentation and nick-end labeling.
NRP-152 actions are dependent on the culture conditions because the application of this chemical and the existing dexamethasone will enhance insulin and IGF will block the apoptosis induced by the transforming growth factor.
Anoabolic Effects in Female Rats
Administering IGF to growing female rats for 14 days by implanting an osmotic pump can cause significant weight gain.
Weight gain effects were application dependent with the highest applications showing 278 ug/day and producing up to 26 percent increases in all measurements.
Human variants of IGF-1 contian amino terminal extension peptides along with glutamate that was found to be more potent for this application than the natural rat version of these chemicals that had weak binding with natural growth factor in the rat’s body.
Muscle protein synthesis as well as myofibrillar protein breakdowns saw an increase when these accretation rates were calculated. The infusion of growth factor that occurred at these levels was not enough to stimulate body growth in the rats. This establishes the idea that IGF peptides will stimulate growth in normal animals, but variants will need to be more active to trigger IGF-1.
Improvement of Remnant Gut Function
Seven days of IGF infusion were measured to determine the absorptive function of gut growth, using rats following up to 80 percent of the removal of the jejuno ileum, compared to analogs of IGF LR3.
It was found that IGF-1 had poor binding to natural IGF proteins while administrations of IGF LR3 saw a significant attenuated malabsorbption of nitrogen and fat. Responses to rats with 80 percent conversions of efficiencies. This was shown in food conversion and body weight gain.
Total gut weights increased by 21 percent with predominately increased small bowel and stomach weights. The potency of this advantage was less noticeable. This led to the conclusion that administering IGF peptides can help to improve absorption of gastro intestinal function.
IGF is considered to be the primary mediator for the effects of growth hormone in animals when growth hormone is secreted from the anterior pituitary gland. IGF stimulates systemic body growth which can be used on every cell in the body, to create new tissues as the body demands. It can also assist with cellular DNA synthesis as necessary.